Biocide and biopesticide compositions are provided. The compositions include mixtures of essential oils and carriers, the combined effect of which provides repelling and/or killing effects against arthropod pests and internal parasites. Methods of controlling and treating for arthropod pests and internal parasites using the disclosed compositions are also provided.

The present invention relates to a composition for use as an oral anti-parasitic, the composition comprises one or more of an essential oil which contains gamma-terpinene, and/or carvacrol, and/or thymol, and/or terpinenol, and/or eucalyptol and/or eugenol, an essential oil of genus Cinnamomum, Eugenia, Eucalyptus or a source of saponin. It also relates to a method of preventing or treating parasitic infection in an animal, the method comprising orally administering to said animal a composition comprising one or more of an essential oil which contains gamma-terpinene, and/or carvacrol, and/or thymol, and/or terpinenol, and/or eucalyptol and/or eugenol, an essential oil of genus Cinnamomum, Eugenia, Eucalyptus or a source of saponin.

Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a composition comprising isolated native, bioactive nematicidal crystals formed from a single type of nematicidal crystal protein. The isolated native, bioactive nematicidal crystals are substantially free of any bacterial spores or host bacterial proteins, other than nematicidal crystal protein in the form of a crystal. Methods for making isolated native, bioactive nematicidal crystals are also described. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A.

Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a composition comprising isolated native, bioactive nematicidal crystals formed from a single type of nematicidal crystal protein. The isolated native, bioactive nematicidal crystals are substantially free of any bacterial spores or host bacterial proteins, other than nematicidal crystal protein in the form of a crystal. Methods for making isolated native, bioactive nematicidal crystals are also described. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A.

The present invention relates to compounds of formula I, ##STR00001##
wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and composition for compounds I.

The present invention covers new quinoline compounds of general formula (I), in which A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. ##STR00001##

The present invention covers new quinoline compounds of general formula (I), in which A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. ##STR00001##

Disclosed is use of a compound in preventing and/or treating pathogen infection in animals. The compound is 4-(3-(((2-amino-5-(2-(1-methylpiperidin-4-yl)thiazol-5-yppyridin-3-ypoxy)methyl) phenyl)-2-methylbut-3-yn-2-ol, having a structure of formula I below. The compound can effectively treat diseases (such as feline infectious peritonitis) caused by pathogen (especially virus, such as coronavirus) infection in animals, improves the survival conditions of the animals, and has better commercial value and application prospect in the field of veterinary anti-pathogen (especially virus, such as coronavirus) therapies.

##STR00001##

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.

This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7 and X.sup.8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X.sup.2, X.sup.4, X.sup.6 and X.sup.8 are halogens, and the meta-phenyl substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently chosen from —OH, —OR or —SO.sub.2R″, where R″ are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR.sub.2, where R are alkyl of 1 to 12 carbon atoms or R.sub.2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 on the same side of the plane defined by the macrocycle. The invention also relates to an anticancer and/or antimicrobial and/or antiviral pharmaceutical composition where atropisomers α.sub.4 and α.sub.3β are the main active ingredients, such that the mixture of atropisomers α.sub.4 and α.sub.3β constitutes more than 70% of the atropisomers present in the active ingredient and/or the atropisomer α.sub.4 constitutes more than 20% of the atropisomers present in the pharmaceutical composition.